What HHS's peptide policy does and doesn't do
Published
The interim policy is a draft enforcement decision, not a law or FDA approval, and HHS says it can revisit it if safety problems arise. It lasts until FDA finishes rules on which ingredients pharmacies may use. A patient-safety group urged HHS to hold off. Comments are open for two weeks after the Oct. 30 notice.
Source: Becker's Hospital Review
This is a plain-language summary. Read the original source for full details.